Form 4: Director James Manuso Receives Opus Genetics Stock Grant

Director James S.J. Manuso was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a compensation event.

Summary

• Director James S.J. Manuso acquired 24,367 shares of common stock via a restricted stock unit (RSU) grant.
• The transaction occurred on April 20, 2026.
• The shares were granted at a price of $0, representing equity compensation.
• Following this transaction, the director's total beneficial ownership in the company increased to 317,318 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Alignment of director interests with shareholders through increased equity ownership.
• Standard equity-based compensation structure for board members.

Negatives

• None identified in this filing.

Risks

• Vesting of the restricted stock units is subject to the director's continuing service through the vesting date.

Future Outlook

The restricted stock units vest on the earlier of the one-year anniversary of the grant date or the day prior to the issuer's next annual meeting of stockholders.

Management Comments

• The grant is subject to the Reporting Person's continuing service through the vesting date.

Industry Context

StockSavvy.ai notes that equity grants to board members are a standard corporate governance practice in the biotechnology sector to ensure long-term alignment between leadership and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices for small-cap biotechnology firms.
• The vesting schedule tied to annual meetings is a common mechanism to ensure board continuity.

Stakeholder Impact

• Increased alignment between the director and shareholders due to higher equity stake.

Next Steps

• Vesting of the 24,367 restricted stock units on the earlier of the one-year anniversary or the day prior to the next annual meeting.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, Director Compensation, Equity Grant